Summary #GlomCon

CLINICAL IMPACT:
Current CKD staging doesn't account for proximal tubular damage - a key risk factor for hypomagnesemia in CKD patients. 💊 Mg supplementation showed limited efficacy in proteinuric patients

Read more: doi.org/10.1093/ndt/...
🧵3/3

KEY FINDINGS:
🔍 Proteinuria = higher probability of hypo-Mg (OR 2.2; 95% CI 1.2–4.0), especially in non-diabetics
📈 Higher proteinuria (uPCR) → higher urinary Mg excretion (FE-Mg)
🧪 When proximal tubular markers were included in analysis, the uPCR-FEMg association weakened significantly

🧵2/3

Thanks for sharing! ☺️ I have to admit, my enthusiasm faded when I kept discovering—often buried deep in the manuscript or hidden in the supplements—that their “groundbreaking” findings were based on FMT from a single donor. 🤦‍♂️ The field suffers from weak methodology and poor reporting standards.

This field is exploding with potential! 🚀 But we need better methods and reporting to truly understand the gut-disease connection.

Hope you find this work (~ 2 years) interesting and helpful in your research!

🔎5/5

Our recommendations for better research (short version):
1️⃣ Follow GRAFT guidelines (adapted for human→animal FMT)
2️⃣ Use multiple donors
3️⃣ Include both sexes (if possible)
4️⃣ Verify microbiota colonization
5️⃣ Comprehensive outcome assessment
6️⃣ Transparent reporting

🔎4/5

MAJOR finding: Huge methodological gaps! 📋
🔸 Many studies use single donors (big generalizability problem!)
🔸 86% of studies don't report donor medications
🔸 Methods vary wildly (fresh vs frozen samples, different volumes)
We need standardization!
🔎3/5

What we found:
🔸 IBD, IBS, obesity, colorectal cancer & depression = most studied health issues
🔸 Cancer research focuses heavily on the non-responsivness to immunotherapy
🔸 Cardiovascular and renal outcomes are surprisingly understudied! 💔
🔎2/5